Global Integrase Inhibitors Market Size is valued at USD 15.8 Bn in 2024 and is predicted to reach USD 27.9 Bn by the year 2034 at a 6.0% CAGR during the forecast period for 2025-2034.
Integrase inhibitors are a type of antiretroviral medications that work by inhibiting the viral enzyme integrase, which is responsible for mixing the viral genome into the DNA of the host cell. This is the mechanism of action of integrase inhibitors.
Retroviral reproduction is dependent on integration. Hence, blocking this step can halt the virus's propagation. The high demand for antiretroviral (ARV) medications directly results from many people infected with HIV worldwide. The government is also making efforts to expand HIV testing and treatment options for those who need them. This trend is expected to fuel the need for HIV medications worldwide. Increasing demand for pharmaceuticals to treat HIV infections and an equivalent rise in the number of pharmaceutical companies producing such drugs drives expansion globally and is expected to boost the market expansion in the coming years.
However, the population growth of patients and the high cost of testing during the COVID-19 outbreak may restrain the development of the target market over the predicted time frame. As a result of the global spread of COVID-19, international trade in medical supplies has been disrupted. The pandemic has hampered the expansion of this market because of the uncertainty and interruption in the availability of medications. Furthermore, increasing R&D activities and investments by prominent players are expected to create lucrative growth opportunities in revenue for players operating in the global integrase inhibitors market over the forecast period.
The integrase inhibitors market is segmented based on drug class, indication, distribution channel, and end-user. As per drug class, the market is segmented into first-generation integrase inhibitors, second-generation integrase inhibitors and others. By indication, the market is segmented into HIV infection and other indications. According to the distribution channel, the segmentation includes hospital pharmacies, retail pharmacies, and online pharmacies. the end-user segment comprises hospitals and clinics, research institutes, and others.
The hospital pharmacies category is expected to hold a major share of the global integrase inhibitors market. It is attributed to an increase in HIV-related hospitalizations. The market is expanding as a result of increasing demand for antiretroviral medications used to treat HIV at hospital pharmacies. The journal Nano Materials published a paper detailing the impressive outcomes of using multiclass combination product therapy to alleviate HIV symptoms. Thus, there is a rise in the adoption of antiretroviral medications prescribed by hospital pharmacists to treat HIV. Additionally, the government expands HIV patients' access to testing and treatment.
The segment, hospitals and clinics is projected to grow rapidly in the global integrase inhibitors market owing to an increase in the number of people seeking medical attention and the need for antiretroviral medications, especially in countries such as the US, Germany, UK, China, and India.
The North American integrase inhibitors market is expected to record the maximum market share in terms of revenue in the near future. It can be attributed to the rising number of people living with HIV in the United States. The high number of people who need HIV medication drives up prices.
The existence of major players providing novel HIV medications for treating HIV infection would also contribute to the expansion of the market. Growing demand for HIV treatment medications across industries and the introduction of new drugs and other products also contribute to the expansion of the industry in the region. In addition, Asia Pacific is estimated to grow rapidly in the global integrase inhibitors market because there are more options for care and growing financial support from the business and medical communities.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 27.66 Bn |
| Revenue Forecast In 2034 | USD 40.56 Bn |
| Growth Rate CAGR | CAGR of 6.0% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Bn and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Drug Class, By Indication, By Distribution Channel, By End User |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain;South Korea; South East Asia |
| Competitive Landscape | Gilead Sciences, ViiV Healthcare, Merck & Co., Inc., GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Johnson & Johnson, AbbVie Inc., Janssen, Pharmaceuticals Inc., Theratechnologies Inc., Shionogi & Co. Ltd. |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Integrase Inhibitors Market Snapshot
Chapter 4. Global Integrase Inhibitors Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Drug Class Estimates & Trend Analysis
5.1. By Drug Class, & Market Share, 2024-2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021-2034 for the following By Drug Class:
5.2.1. First-Generation Integrase Inhibitors
5.2.2. Second-Generation Integrase Inhibitors
5.2.3. Others
Chapter 6. Market Segmentation 2: By Indication Estimates & Trend Analysis
6.1. By Indication & Market Share, 2024-2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021-2034 for the following By Indication:
6.2.1. HIV Infection
6.2.2. Other Indications
Chapter 7. Market Segmentation 3: By End User Estimates & Trend Analysis
7.1. By End User & Market Share, 2024-2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021-2034 for the following By End User:
7.2.1. Hospitals and Clinics
7.2.2. Research Institutes
7.2.3. Others
Chapter 8. Market Segmentation 4: By Distribution Channel Estimates & Trend Analysis
8.1. By Distribution Channel & Market Share, 2024-2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021-2034 for the following By Distribution Channel:
8.2.1. Hospital Pharmacies
8.2.2. Retail Pharmacies
8.2.3. Online Pharmacies
Chapter 9. Integrase Inhibitors Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Integrase Inhibitors Market revenue (US$ Million) estimates and forecasts By Drug Class, 2021-2034
9.1.2. North America Integrase Inhibitors Market revenue (US$ Million) estimates and forecasts By Indication, 2021-2034
9.1.3. North America Integrase Inhibitors Market revenue (US$ Million) estimates and forecasts By End User, 2021-2034
9.1.4. North America Integrase Inhibitors Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2021-2034
9.1.5. North America Integrase Inhibitors Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
9.2. Europe
9.2.1. Europe Integrase Inhibitors Market revenue (US$ Million) By Drug Class, 2021-2034
9.2.2. Europe Integrase Inhibitors Market revenue (US$ Million) By Indication, 2021-2034
9.2.3. Europe Integrase Inhibitors Market revenue (US$ Million) By End User, 2021-2034
9.2.4. Europe Integrase Inhibitors Market revenue (US$ Million) By Distribution Channel, 2021-2034
9.2.5. Europe Integrase Inhibitors Market revenue (US$ Million) by country, 2021-2034
9.3. Asia Pacific
9.3.1. Asia Pacific Integrase Inhibitors Market revenue (US$ Million) By Drug Class, 2021-2034
9.3.2. Asia Pacific Integrase Inhibitors Market revenue (US$ Million) By Indication, 2021-2034
9.3.3. Asia Pacific Integrase Inhibitors Market revenue (US$ Million) By End User, 2021-2034
9.3.4. Asia Pacific Integrase Inhibitors Market revenue (US$ Million) By Distribution Channel, 2021-2034
9.3.5. Asia Pacific Integrase Inhibitors Market revenue (US$ Million) by country, 2021-2034
9.4. Latin America
9.4.1. Latin America Integrase Inhibitors Market revenue (US$ Million) By Drug Class, (US$ Million) 2021-2034
9.4.2. Latin America Integrase Inhibitors Market revenue (US$ Million) By Indication, (US$ Million) 2021-2034
9.4.3. Latin America Integrase Inhibitors Market revenue (US$ Million) By End User, (US$ Million) 2021-2034
9.4.4. Latin America Integrase Inhibitors Market revenue (US$ Million) By Distribution Channel, (US$ Million) 2021-2034
9.4.5. Latin America Integrase Inhibitors Market revenue (US$ Million) by country, 2021-2034
9.5. Middle East & Africa
9.5.1. Middle East & Africa Integrase Inhibitors Market revenue (US$ Million) By Drug Class, (US$ Million) 2021-2034
9.5.2. Middle East & Africa Integrase Inhibitors Market revenue (US$ Million) By Indication, (US$ Million) 2021-2034
9.5.3. Middle East & Africa Integrase Inhibitors Market revenue (US$ Million) By End User, (US$ Million) 2021-2034
9.5.4. Middle East & Africa Integrase Inhibitors Market revenue (US$ Million) By Distribution Channel, (US$ Million) 2021-2034
9.5.5. Middle East & Africa Integrase Inhibitors Market revenue (US$ Million) by country, 2021-2034
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Gilead Sciences
10.2.2. ViiV Healthcare
10.2.3. Merck & Co., Inc.
10.2.4. GlaxoSmithKline PLC
10.2.5. Bristol-Myers Squibb Company
10.2.6. Johnson & Johnson
10.2.7. AbbVie Inc.
10.2.8. Janssen
10.2.9. Pharmaceuticals, Inc.
10.2.10. Theratechnologies Inc.
10.2.11. Shionogi & Co., Ltd.
Integrase Inhibitors Market By Drug Class-
Integrase Inhibitors Market By Indication-
Integrase Inhibitors Market By Distribution Channel-
Integrase Inhibitors Market By End User-
Integrase Inhibitors Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-